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The unfolded protein responsemediates reversible tau
phosphorylation induced by metabolic stress
JM van der Harg1, A No¨lle1, R Zwart1, AS Boerema2, ES van Haastert3, AM Strijkstra2, JJM Hoozemans3 and W Scheper*,1,4,5
The unfolded protein response (UPR) is activated in neurodegenerative tauopathies such as Alzheimer’s disease (AD) in close
connection with early stages of tau pathology. Metabolic disturbances are strongly associated with increased risk for AD and are
a potent inducer of the UPR. Here, we demonstrate that metabolic stress induces the phosphorylation of endogenous tau via
activation of the UPR. Strikingly, upon restoration of the metabolic homeostasis, not only the levels of the UPR markers pPERK,
pIRE1a and BiP, but also tau phosphorylation are reversed both in cell models as well as in torpor, a physiological
hypometabolic model in vivo. Intervention in the UPR using the global UPR inhibitor TUDCA or a specific small-molecule
inhibitor of the PERK signaling pathway, inhibits the metabolic stress-induced phosphorylation of tau. These data support a role
for UPR-mediated tau phosphorylation as part of an adaptive response to metabolic stress. Failure to restore the metabolic
homeostasis will lead to prolonged UPR activation and tau phosphorylation, and may thus contribute to AD pathogenesis. We
demonstrate that the UPR is functionally involved in the early stages of tau pathology. Our data indicate that targeting of the UPR
may be employed for early intervention in tau-related neurodegenerative diseases.
Cell Death and Disease (2014) 5, e1393; doi:10.1038/cddis.2014.354; published online 28 August 2014
Several neurodegenerative disorders are characterized by
abnormal phosphorylation and aggregation of the neuron-
specific microtubule-binding protein tau.1 These so-called
tauopathies include highly prevalent neurodegenerative
disorders as Alzheimer’s disease (AD) and tau-related
frontotemporal dementias, for which at present no effective
treatment exists. To develop a disease-modifying intervention
strategy, it is pivotal to understand early molecular events that
lead to the increased phosphorylation of tau. In pathological
situations such as AD, tau is hyperphosphorylated and forms
aggregates, but under physiological conditions tau phospho-
rylation and dephosphorylation are a normal dynamic
process. Phosphorylation of tau reduces the binding of tau
to microtubules and regulates the function of tau in axonal
transport.2
It has been hypothesized that initially increased tau
phosphorylation is a protective mechanism, which may turn
pathological if it is present for a prolonged period.3 For
example, metabolic stress conditions could lead to increased
phosphorylation of tau as part of an adaptive response, by
temporarily inhibiting energy-costly axonal transport. In line
with this, increased tau phosphorylation is observed in brains
of animals in torpor, which is a physiological hypometabolic
situation whereby the metabolic rate can be reduce by 90%.4
This is often facilitated by a reduction in body temperature,
although this is not an absolute prerequisite.5,6 In brains of
mammals undergoing torpor, tau is hyperphosphorylated and
not aggregated. In this physiological situation, the tau
phosphorylation is reversed when the animals return to their
normal metabolic state. Various in vivo studies demonstrate
that tau phosphorylation is also increased in pathological
metabolic stress situations (e.g., diabetes type I and II;
treatment with a mitochondrial uncoupler).5,7–11 In this case,
the metabolic stress is persistent and tau aggregates are
formed. Interestingly, metabolic dysfunction is a prominent
risk factor for the development of AD.12
Our lab and others have previously shown that the unfolded
protein response (UPR), the stress response of the endo-
plasmic reticulum (ER), is activated in the earliest pathological
stages in brains of patients with tauopathies.13–16 The ER is
strategically positioned to sense and integrate metabolic
signals. It is an important site for crucial steps in protein,
lipid and glucose metabolism. The UPR is initiated upon
disturbance of the homeostasis in the ER via activation of
three sensor proteins in the ER membrane: PERK, ATF6 and
IRE1. Activation of these sensors transfers stress signals to
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the cytoplasm and the nucleus, resulting in overall inhibition of
protein translation and increased transcription and translation
of genes involved in the restoration of ER homeostasis.17
In brains of AD patients, the UPR is activated in neurons
containing diffusely distributed phosphorylated tau (p-tau), but
not in neurons with densely aggregated tau, suggesting that
UPR activation occurs before the formation of end-stage tau
inclusions, the tangles.15,18 This strong correlation between
UPR activation and early stages of p-tau accumulation is not
only found in AD but also in other tauopathies.16 Interestingly,
the p-tau in torpor brain is reminiscent of p-tau present in
neurons undergoing UPR activation in brains of tauopathy
patients: hyperphosphorylated at the same epitopes and not
aggregated.19 Moreover, in vitro and in vivo data demonstrate
that treatment with thapsigargin, which activates the UPR via
disturbance of calcium homeostasis, is accompanied by
increased tau phosphorylation, suggesting there may be a
direct functional connection between UPR activation and
tau phosphorylation.20,21 Metabolic stress is an important
physiological trigger of the UPR. In this study, we investigated
whether UPR activation functionally connects metabolic
dysfunction and tau phosphorylation as part of a reversible
adaptive response.
Results
Temporal and spatial correlation of reversible UPR and
p-tau in a hypometabolic model. To investigate whether
p-tau in the torpid brain is also associated with UPR
activation, brains of hamsters in euthermia, early torpor, late
torpor, and after arousal were analyzed. Antibodies for
phosphorylated PERK (pPERK) and phosphorylated IRE1a
(pIRE1a) were used as markers for UPR activation in
combination with AT8, a p-tau antibody. In the euthermic
state UPR activation and p-tau are not detected, whereas in
early and late torpor massive UPR activation and p-tau is
observed in the hippocampus (Figure 1a) and cortex
(Figure 1b). There is no obvious difference visible between
early and late torpor. Interestingly, pPERK, pIRE1a and p-tau
disappear again completely after arousal when metabolism
and temperature are restored (Figures 1d, h and l).
Quantification of the images confirms the strong induction
of UPR activation and p-tau in early torpor and late torpor
(20–80 fold increased relative to euthermia) in the cortex and
hippocampus (Figure 2). pPERK and p-tau positivity are not
significantly different between early and late torpor and show
a similar pattern throughout the hibernation cycle (Figures 2b
and c). The pIRE1a staining shows a decrease in late torpor
compared with early torpor in the cortex and hippocampus,
but the levels are still 40–60 fold higher than under euthermic
conditions (Figure 2a). Interestingly, quantification of the
UPR markers and p-tau shows no significant difference
between arousal and euthermia, indicating that UPR activa-
tion and tau phosphorylation are fully reversible processes,
which are only activated during torpor. It has been reported
that during torpor tau is phosphorylated at multiple sites;5
western blotting of Syrian hamster brain lysates during
euthermia, torpor and arousal confirms that also tau
phosphorylation at Ser396 is increased during torpor and
reversed upon arousal (Supplementary Figure 1).
The pPERK, pIRE1a and p-tau reactivities show similar
distribution between brain areas. In many areas positive cells
are observed during torpor, but the intensity and the number of
positive cells varies between brain regions; cortex and
hippocampus show the most pronounced positivity,
whereas the striatum is virtually negative (Figures 2a–c;
Supplementary Figure 2). To investigate this spatial correla-
tion in more detail, double immunofluorescence was
performed and analyzed by confocal microscopy. The
immunohistochemistry shows that pPERK and pIRE1a are
present in the cell bodies of neurons but not in neurites or
axons, whereas p-tau is detected in neuronal cell bodies, but
also in neurites and very prominently in axons (Figure 3). The
confocal pictures show that, like in the human AD brain,15
pPERK and pIRE1a are present as punctate structures in the
soma, whereas p-tau shows a more diffuse distribution
throughout the cell. Interestingly, despite their different
subcellular distribution, 475% of the neurons display UPR
activation as well as p-tau (Figures 3d and h). Isolated p-tau
staining is observed in o14% and single pPERK or pIRE1a
staining in o10% of the neurons. These data demonstrate
that UPR activation and tau phosphorylation during torpor
occur in the same neurons in specific brain areas. Striking is
the reversibility of both UPR activation and tau phosphoryla-
tion during arousal when metabolism returns to normal.
The UPR is activated bymetabolic stress and consolidated
by hypothermia. It is clear that the UPR is activated
during torpor; however, it is not known whether this is due
to a passive temperature-driven regulation, or that it is
actively induced by a torpor-related mechanism. Both
pPERK and pIRE1a that were used as UPR markers in the
hamster brain in torpor are activated by phosphorylation. It
has been reported that the activity of phosphatases
decreases exponentially at temperatures lower than
37 1C,22 which can potentially cause a passive increase in
the levels of these markers. Therefore, we analyzed the
phosphorylation of PERK in an in vitro model. Differentiated
human neuronal SK-N-SH cells were incubated at euthermic
temperature of 37 1C and at 26 1C to investigate UPR
activation at decreased temperatures. In addition, the
differentiated SK-N-SH cells were treated with two different
UPR inducers, tunicamycin (TM) and 2-deoxy glucose
(2DG). 2DG inhibits glucose metabolism at the first step of
glycolysis and thus blocks ATP production from glucose,
similar to the drastic decrease in metabolism that occurs
during torpor. The phosphorylation of PERK is readily
increased at 37 1C upon treatment with TM and 2DG
(Figure 4), as expected. However, lowering the temperature
to 26 1C does not induce pPERK levels. Moreover, the
induction of PERK phosphorylation by TM or 2DG is
completely abolished at 26 1C. Because the UPR affects
transcription, translation and phosphorylation, we analyzed
more UPR targets at mRNA and protein levels at different
time points. We obtained similar results for all targets
demonstrating that hypothermia does not result in UPR
activation (Supplementary Figures 3 and 4). Our data
demonstrate that the UPR sensors as well as the down-
stream signaling of the UPR is not spontaneously activated
at lower temperatures and therefore UPR activation is not a
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non-specific side effect of hypothermia. Moreover, stress-
induced activation of the UPR is severely impaired under
hypothermic conditions (Figure 4; Supplementary Figures 3
and 4). We therefore explored the hypothesis that the UPR
activation observed during torpor is induced during euthermia
and subsequently consolidated by the hypothermic state. To
test this, SK-N-SH cells were incubated for 20 h at 37 and
26 1C. BiP mRNA levels were used as a readout for UPR
activation, as similar results were found for all UPR targets in
the previous experiments. In line with our hypothesis, we
demonstrate that if the UPR is activated upon metabolic
stress for 20 h at 37 1C it remains activated after 20 h at
26 1C, even if the metabolic stressor is removed. Interest-
ingly, if the cells are subsequently moved to 37 1C for another
20 h without a metabolic stressor, the BiP mRNA levels
return to normal (Figure 5). If the metabolic stressor is not
removed the UPR remains activated, as expected. These
data demonstrate that if the UPR is activated during
euthermia, this activation is consolidated during hypother-
mia, but that upon restoration of normal metabolic conditions
at 37 1C the UPR is switched off. These results further
strengthen the hypothesis that the UPR is an adaptive
Figure 1 Temporal correlation between UPR activation and p-tau. Coronal brain sections of wild-type Syrian hamsters were studied during euthermia, early torpor, late
torpor and arousal. For each condition three to five animals were used for immunohistochemistry. All animals of the same condition showed similar staining patterns.
Representative immunohistochemical staining of UPR activation and p-tau in the hippocampus (A) and in the cortex (B) are shown. pIRE1a (a–d) and pPERK (e–h) are
markers for UPR activation, and AT8 (i–l) detects p-tau. During euthermia (a, e and i) there are no pIRE1a-, pPERK- and AT8-positive cells, but during early (b, f and j) and late
torpor (c, g and k) there is abundant reactivity for these markers. During arousal the reactivity of all markers is dissipated (d, h and l). Scale bar: 100mm
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response that is actively induced under physiological
hypometabolic conditions and actively reversed upon
restoration of energy homeostasis.
Metabolic stress induces reversible p-tau via the UPR.
Because UPR activation and tau phosphorylation are
observed together not only under pathological but also under
physiological conditions in the brain, it is likely that there is a
direct functional connection between the two events. To test
this, differentiated SK-N-SH cells were treated with the UPR
inducer TM for 20 h. The phosphorylation of tau at Ser396 is
significantly increased in TM-treated cells (Figure 6a).
Interestingly, when differentiated SK-N-SH cells were treated
with 2DG for 20 h to induce similar metabolic stress that
occurs during torpor, tau phosphorylation is significantly
increased (Figure 6b). No change in the total tau levels
were observed in TM- and 2DG-treated cells (Figure 6).
This demonstrates that tau phosphorylation is induced by
UPR activation. In addition, the data show that metabolic
stress is an activator of the UPR that leads to increased
p-tau levels. In combination with our observations in the
hypometabolic brain in vivo, these data suggest that tau
phosphorylation is part of the UPR-mediated adaptive
response to metabolic stress. To investigate whether tau
phosphorylation is a normal physiological process that is
reversible upon restoration of metabolic homeostasis, the
UPR was activated in differentiated SK-N-SH cells for 20 h
with 2DG. Subsequently the cells were incubated for another
20 h in the presence or absence of a metabolic stressor.
The levels of p-tau are increased in the continuous presence
of the metabolic stressor, as expected (Figure 7). However,
if the metabolic stressor is removed and washed away,
p-tau levels return to normal (Figure 7), like UPR
activation (Figure 5). In support of an adaptive mechanism,
Figure 2 UPR and p-tau quantification of different brain areas during torpor. Coronal brain sections of wild-type Syrian hamsters were studied during euthermia, early
torpor, late torpor and arousal. Images of the cortex, hippocampus and striatum of each animal were acquired with  20 objective and identical microscope settings. ImageJ
software with threshold color plugin was used to quantify the images (see Materials and Methods for details). The positive pixels (mean±S.E.M. of n¼ 3–5 animals per group)
of pIRE1a (a), pPERK (b) and AT8 (c) in cortex, hippocampus and striatum are shown. The quantification of positive reactivity demonstrate high levels of pIRE1a, pPERK and
AT8 during early torpor (TE) and late torpor (TL) in cortex and hippocampus and almost no positive reactivity during euthermia (EU) and arousal (A) (*Po0.05 relative to EU,
**Po0.01 relative to EU, #Po0.05 TE relative to TL)
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these data demonstrate that both UPR activation and tau
phosphorylation are reversed upon restoration of metabolic
homeostasis.
If the UPR is key to metabolic stress-induced tau
phosphorylation, intervention in the UPR may provide an
opportunity to prevent this early event in tau pathology. To
inhibit the proteotoxic stress in the ER induced by 2DG, we
employed the chemical chaperone tauroursodeoxycholic acid
(TUDCA), which effectively inhibits overall UPR activation and
thus of its downstream targets.23,24 To confirm the effect of
TUDCA, phosphorylated eIF2a (p-eIF2a), which is phos-
phorylated by activated PERK, was measured. Differentiated
SK-N-SH cells were pre-treated with TUDCA for 1 h before the
metabolic stressor 2DG was added to the medium for 20 h.
Indeed, TUDCA inhibits the 2DG-induced increase in p-eIF2a
levels, as expected (Figure 8). Interestingly, this inhibition of
the UPR also prevents 2DG-induced tau phosphorylation.
This demonstrates not only that the increase in p-tau upon
metabolic stress is mediated by the UPR, but also identifies
the UPR as a putative target for therapeutic intervention.
Recently, a selective inhibitor of the PERK pathway of the
UPR has become available, GSK2606414.25 To test this small
molecule, differentiated neuronal SK-N-SH cells were pre-
treated with the PERK inhibitor for 1 h before the metabolic
stressor 2DGwas added to themedium for 20 h. Pretreatment
with GSK2606414 inhibits the 2DG-induced increase in
p-eIF2a levels, validating that it inhibits PERK activity in the
human neuronal cell model (Figure 8). More importantly,
inhibition of the PERK pathway by this compound also
prevents the phosphorylation of tau upon treatment with
2DG. This implicates that intact UPR signaling is required for
tau phosphorylation under metabolic stress and provides the
first evidence that interference in the UPR is a possible
therapeutic target in tauopathies.
Discussion
In the present study, we investigated whether UPR activation
functionally connects metabolic dysfunction and tau phos-
phorylation. We demonstrate that metabolic stress activates
the UPR resulting in increased tau phosphorylation. This adds
to earlier data that show that thapsigargin treatment leads to
tau phosphorylation.20,21 Thapsigargin induces the UPR via
disruption of ER Ca2þ homeostasis, however, it affects many
different processes. Here, we show that two other inducers of
the UPR – TM and 2DG – also result in tau phosphorylation.
Moreover, we demonstrate involvement of the UPR using the
chemical chaperone TUDCA and a selective inhibitor of the
PERK pathway. A very interesting and striking observation is
the concomitant reversibility of UPR activation and p-tau after
return to the normal physiological state both in vitro and
in vivo.
The p-tau observed in torpor is not aggregated and
resembles the pre-tangle stages of tau pathology, in which
we observe activation of the UPR in the human brain.15
Figure 3 Spatial correlation between UPR activation and p-tau. Coronal brain sections of wild-type Syrian hamsters in early torpor and late torpor were analyzed by
double-immunofluorescence staining of UPR markers (pIRE1a and pPERK) and p-tau (AT8). Representative double-immunofluorescent images of early torpor obtained by
confocal microscopy are shown. pIRE1a (a) and pPERK (e) are depicted in red and AT8 (b and f) in green. The overlays of the markers demonstrate colocalization of pIRE1a
and AT8 (c) and colocalization of pPERK and AT8 (g) in the same neuron. Quantification of cells with positive reactivity (mean±S.E.M. of n¼ 120) demonstrate that475%
of the neurons show both UPR activation and p-tau (d and h). Scale bar: 10mm
Figure 4 Hypothermia does not elevate pPERK levels. Differentiated SK-N-SH
cells were incubated at 37 or 26 1C for 20 h in the absence (Con) or presence of
UPR inducers: 0.2 and 0.5mg/ml TM and 40 mM 2DG. Immunoprecipitation and
western blot analyze of pPERK was performed. There is no induction of pPERK at
26 1C in the untreated condition. An increase of pPERK is visible at 37 1C after 20 h
treatment with TM and 2DG. This elevation of pPERK after treatment is not
observed at 26 1C. All data are presented as mean±S.D. of an experimental n¼ 3
and normalized to the untreated 37 1C control condition (*Po0.05, **Po0.01)
Metabolic stress induces p-tau via the UPR
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Reduction of the temperature below 37 1C was previously
shown to disturb the balance between tau kinase and
phosphatase activity, and this has been suggested to cause
increased tau phosphorylation as a result of a passive
temperature-driven mechanism.22 In a recent and more
extensive study, however, it was shown that the phosphoryla-
tion of tau is first actively induced as animals go into torpor and
that this is passively consolidated by the lower temperature as
a secondary event.5 Here, we demonstrate that in analogy to
the torpor-induced phosphorylation of tau not hypothermia but
hypometabolic stress is involved in the activation of the UPR,
and that the UPR remains activated during the hypothermic
state. Interestingly, in torpor UPR activation and p-tau
followed a certain spatial hierarchy associated with energy
metabolism. The cortex and hippocampus showed the most
pronounced UPR activation and p-tau, whereas other areas
such as the striatum showed almost no positive cells. These
areas with high UPR activation and p-tau levels are areas that
typically have a high metabolic demand,26 suggesting that
metabolic stress is a critical factor. Interestingly, these
metabolically demanding regions are also the brain areas
that are affected early in AD.27
Metabolic stress has already been described as an
important feature in AD. The majority of AD patients display
abnormal glucose metabolism, ranging from glucose intoler-
ance to insulin resistance and type 2 diabetes mellitus.28
A reduced glucose metabolic rate is already observed in
patients that are genetically predisposed to develop AD before
any pathological signs of the diseasemanifest.29,30 Moreover,
glucose metabolism is also decreased in brains of patients
with mild cognitive impairment, which is a prodromal stage of
AD.31–34 Recent data show that in cognitively normal subjects
with early signs of disturbed peripheral glucose metabolism,
glucose utilization is impaired in brain areas affected in AD.35
This indicates that peripheral metabolic dysfunction is
associated with hypometabolism in the brain that is not
necessarily a downstream effect of neurodegeneration. It is
interesting to note that in a recent GWAS study, GLIS3, a
major factor in glucose metabolism, was associated with
increased tau levels in the cerebrospinal fluid, an early
biomarker for AD-related changes in the brain.36
Figure 5 Activation of the UPR during euthermia is consolidated during
hypothermia. Differentiated SK-N-SH cells were sequentially incubated at 37 1C for
20 h, at 26 1C for 20 h and again at 37 1C for 20 h. Cells were treated in the absence
or presence of 2DG to induce metabolic stress, and 2DG was added or removed at
each subsequent temperature change as indicated. After each incubation period of
20 h, BiP mRNA levels were determined by qPCR; eEF2a was used as a reference
gene. Data are presented as mean±S.D. in arbitrary units (AU) from triplicate
observations of a representative experiment and are normalized to the untreated
samples with the same incubation time. BiP mRNA levels are consolidated at 26 1C
in the absence of 2DG and are reversed upon restoration of metabolic homeostasis
by removal of 2DG at 37 1C (*Po0.05, **Po0.01)
Figure 6 Metabolic stress functionally connects UPR activation and tau
phosphorylation. Differentiated SK-N-SH cells were treated with TM (a) or 2DG
(b) for 20 h. Representative western blot of n¼ 3 is shown. Tau Ser396
phosphorylation (p-tau) is increased after treatment with TM and 2DG. Total tau is
not changed. Quantification of p-tau and tau is relative to loading control eEF2a.
This experiment shows that UPR activation induces tau phosphorylation (*Po0.01)
Figure 7 UPR activation and p-tau are reversed upon restoration of metabolic
homeostasis. Differentiated SK-N-SH cells are treated with 2DG for 20 h.
Subsequently the cells were incubated for another 20 h with or without 2DG.
Representative western blot (a) and quantification (b) of tau Ser396 phosphorylation
(p-tau) of n¼ 3 is shown. After 40 h p-tau levels are increased after 2DG treatment,
but are reversed if 2DG is removed. This experiment demonstrates the reversibility
of UPR-induced tau phosphorylation upon restoration of metabolic homeostasis
(*Po0.05)
Figure 8 Inhibition of UPR prevents p-tau upon metabolic stress. Differentiated
SK-N-SH cells were treated 20 h with 2DG alone or in the presence of TUDCA
(2DGþ T), a UPR inhibitor or a selective PERK inhibitor (2DGþPI).
Representative western blot of n¼ 3 is shown. Tau Ser396 phosphorylation
(p-tau) is significantly increased after treatment with 2DG, but is not significantly
increased in presence of TUDCA or the PERK inhibitor. Quantification of p-tau is
relative to total tau levels. P-eIF2a, the first downstream target of activated PERK, is
shown as an indicator of UPR activation. eEF2a is used as a loading control. This
experiment shows that p-tau can be prevented by inhibition of the UPR via the
PERK pathway (*Po0.01)
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We hypothesize that metabolic stress induces UPR
activation and tau phosphorylation in the brain as a reversible
neuroprotective response. In line with this, we find that return
to normal physiological metabolic conditions reverses both
activation of the UPR and phosphorylation of tau in vitro and
in vivo. However, if the hypometabolic state persists due to
fundamental metabolic problems, for example, because of
insulin resistance as was demonstrated to occur in AD
hippocampus,37 this may eventually lead to irreversible tau
aggregation. These tau aggregates can then in turn contribute
to prolonged UPR activation by interfering with ER-associated
degradation, as was recently shown to occur in a transgenic
tau model with a very aggressive phenotype.38,39 This further
underlines the risk of prolonged UPR activation and the
importance of balanced regulation.
Our data add to accumulating evidence that puts the UPR in
the frame as an early therapeutic target for neurodegenerative
diseases.40,41 In fact, interference in the UPR by deletion of
the gene encoding PERK, EIF2AK3, or by administration of a
selective PERK inhibitor similar to the one used in this study to
inhibit UPR-induced tau phosphorylation showed beneficial
effects in animal models for neurodegeneration.42–44 These
effects are mediated via rescue of the attenuation of protein
synthesis. In addition, here we show that inhibition of PERK
reduces UPR-induced tau phosphorylation, indicating that the
PERK pathway is at least involved in UPR-mediated tau
phosphorylation. Interestingly, a polymorphism in the
EIF2AK3 gene was shown to be associated with risk to
develop progressive supranuclear palsy (PSP), another
neurodegenerative tauopathy.45 In brains of PSP patients,
UPR activity is found in neurons with diffuse p-tau, as in AD.16
This underlines the importance of proper PERK function in the
protection against tau pathology.
Although our data suggest that tau phosphorylation upon
metabolic stress is mediated by the UPR, it is still elusive how
the UPR affects the activity of tau kinases or phosphatases.
For one of the major tau kinases, glycogen synthase kinase 3,
it was demonstrated that the UPR increases the activity,21,46
but it is not known how this works mechanistically. UPR
activation may also lead to downregulation of phosphatases,
by inhibition of the activity via phosphorylation. As IRE1 and
PERK are kinases with an increasing list of substrates,41 this
could be a direct effect of these kinases or indirect via
activation of a downstream substrate kinase. Finally, the
levels of phosphatases or kinases may be regulated by
activation of the transcriptional IRE1 and ATF6 pathways of
the UPR. Alternatively, the PERK pathway has drastic effects
on the proteome via the overall translation inhibition and
increased translation of selective mRNAs, the latter also
leading to increased transcription of target genes of activating
transcription factor 4 (ATF4). Future studies will be directed at
elucidation of the signaling pathway that connects UPR
activation to p-tau, to develop selective therapeutic interven-
tion methods.
In conclusion, we present the first evidence for a connection
between UPR activation and tau phosphorylation as a
physiological metabolic stress mechanism not primarily
associated with pathology. Importantly, the reversibility of
both UPR activation and tau phosphorylation indicates that
intervention in UPR regulation may not only prevent, but
possibly even dissipate early tau accumulations in the
tauopathy brain.
Materials and Methods
Syrian hamsters. This study was performed with wild-type Syrian hamsters
(Mesocricetus auratus) derived from the breeding colony in Haren, University of
Groningen. Hamsters were housed in Macrolon type 3 cages on sawdust bedding,
with hay as nesting material. Water and food were available ad libitum throughout
the experiment. Syrian hamsters were subjected to torpor conditions as previously
described.19 A control group, the euthermic group (EU), was continuously housed
at 21 (±1) degree and summer photoperiod (14 h of light and 10 h of darkness).
Animals in the EU group were sampled in the inactive phase. Animals in the
experimental group were killed at different time points during torpor: animals in
early torpor (TE) were sampled after 24.1 h (S.E.M. 0.51 h) of inactivity, animals in
late torpor (TL) were sampled after 94.7 h (S.E.M. 2.93 h) of inactivity and animals
in the arousal group were sampled 2.5 h (S.E.M. 0.04 h) after induction of arousal
from torpor. Mouth temperatures of the animals, taken at the moment of killing,
confirmed the state of the animals: TE: 6.6 1C (S.E.M. 0.18 1C), TL: 6.8 1C (S.E.M.
0.47 1C), arousal: 32.1 1C (S.E.M. 0.8 1C) and EU: 35.4 1C (S.E.M. 0.39 1C).
Syrian hamsters were killed by intraperitoneal injection of 60 mg/kg pentobarbital.
Subsequently brains were dissected and frozen in  80 1C for protein lysates or
animals were transcardially perfused with 100 ml phosphate-buffered saline (PBS)
followed by 300 ml 4% paraformaldehyde in 0.1 M PBS. Brains were dissected,
post-fixated for 24 h in 4% paraformaldehyde in 0.1 M PBS at 6 1C, and stored in
PBS with 1% sodium azide at 6 1C for later immunohistochemistry analysis. The
experiments were conducted by following the principles of laboratory animal care
and were approved by the Animal Experiments Committee of the University of
Groningen (license number DEC—2954).
Cell culture, differentiation and treatment. SK-N-SH, a human
neuroblastoma cell line (European Collection of Cell Cultures #86012802,
Salisbury, UK), was cultured in Dulbecco’s modified Eagle’s medium with
GlutaMAX supplemented with 10% (v/v) fetal calf serum (Sigma, St Louis, MO,
USA), 100 U/ml penicillin and 100mg/ml streptomycin. Before treatment, cells were
kept at 37 1C, 5% CO2 and 95% humidity. SK-N-SH cells were differentiated with
trans-retinoic acid (Sigma) at a final concentration of 10 mM for 5–10 days. In
general, to activate the UPR, cells were treated with 0.2 or 0.5mg/ml TM or with
40 mM 2DG at 37 1C. To inhibit UPR activation, SK-N-SH cells were preincubated
for 1 h with 5 mM TUDCA or 0.3mM PERK inhibitor I, GSK2606414 (PI) (Millipore,
Billerica, MA, USA). For the hypothermia experiments, cells were incubated
between 26 and 37 1C as indicated. All temperature conditions were normalized
and compared with simultaneously incubated 37 1C control condition. To test the
reversibility of the UPR, cells were subsequently incubated for 20 h at 37, 26 and
37 1C. The metabolic stressor 2DG was removed by washing the cells two times
with regular medium.
Immunoprecipitation. SK-N-SH cells were plated and differentiated in 9-cm
dishes. After treatment, cells were scraped in 500ml of lysis buffer (1% Triton
X-100, 150 mM NaCl, 20 mM Hepes pH7.5, 10% glycerol, 1 mM EDTA
supplemented with protease inhibitors (complete protease inhibitors from Roche,
Penzberg, Germany) and phosphatase inhibitors (PhosSTOP, Roche). The lysate
(supernatant) was obtained after 5 min spin at 4 1C. Supernatant protein content
was determined by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA).
Total lysate was precleared with 15ml washed protein G-Sepharose for 60 min at
room temperature. For immunoprecipitation 1 mg lysate was incubated with 2mg
PERK antibody linked to 15ml of packed volume of protein G-Sepharose
under rotation at 4 1C overnight. Proteins were washed three times with lysis
buffer and once with PBS. Subsequently, proteins were boiled at 95 1C for 5 min
and supernatant was used for SDS-PAGE and western blotting of pPERK and
PERK.
SDS-PAGE and western blotting. Cells were harvested by scraping in
1% Triton X-100 TBS lysis buffer supplemented with protease and phosphatase
inhibitors. Cell lysates were vigorously mixed after 5 min incubation on ice and
centrifuged for 5 min at 20 000 g at 4 1C. Supernatant protein content was
determined by the Bio-Rad Protein Assay (Bio-Rad). Equal amounts of protein
were loaded on appropriate percentage polyacrylamide gels, 8% for BiP and 10%
for the other proteins and blotted onto PVDF membrane (Millipore) using a
semi-dry electroblotting apparatus. Blots were preincubated with 5% bovine serum
Metabolic stress induces p-tau via the UPR
JM van der Harg et al
7
Cell Death and Disease
albumin (Boehringer, Mannheim, Germany) in TBS-T (0.05% Tween-20 in TBS)
for 60 min at room temperature and subsequently incubated at 4 1C overnight with
primary antibodies. Membranes were washed 3 10 min in TBS-T and
subsequently incubated with species-specific secondary antibodies conjugated
to horseradish peroxidase (dilution 1 : 2000, Dako, Glostrup, Denmark). Reactive
protein bands were visualized using LumiLightPLUS Western blotting substrate
(Roche Applied Science, Penzberg, Germany) and a LAS-3000 luminescent
image analyzer (Fuji Photo Film (Europe), Kleve, Germany). Results were
analyzed using Advanced Image Data Analyzer software (Raytest, Straubenhardt,
Germany) version 3.44.035. The control and treated samples were all loaded on
the same SDS-PAGE gel. The primary antibodies and their dilution factors are
listed in Table 1.
RNA isolation, cDNA synthesis and real-time qPCR. Cells were
lysed and scraped in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and organic-
and aqueous phase separation was initiated by the addition of and mixing with
chloroform (Merck, Whitehouse Station, NJ, USA). Subsequently, RNA isolation
was performed automated with an RNeasy MiniKit on a Qiacube (Qiagen, Venlo,
the Netherlands; according to the manufacturer’s protocol). RNA purity and
integrity was assessed spectrophotometrically on a NanoDrop 2000 spectro-
photometer (Thermo Scientific, Waltham, MA, USA). cDNA synthesis was
performed on 0.5–1.0mg of RNA per reaction (RNA sample quantities do not vary
within each experiment) using a SuperScript II Reverse Transcriptase Kit
(Invitrogen). Priming of mRNA poly-A tails was performed with 125 pmol
oligo(dT)12-VN primer in a final volume of 10 ml and was incubated at 70 1C for
10 min. MgCl2 (2 mM), dNTPs (0.5 mM), 5ml 5 First-Strand Buffer and 100 U
SuperScript II reverse transcriptase were added to the primed mRNAs in a final
volume of 25ml per reaction and incubated at 42 1C for 60 min. The reverse
transcription reaction was stopped by incubation at 70 1C for 10 min. Per sample
1ml cDNA was pipetted in triplicate into a 384-well plate and dried in a DNA110
SpeedVac (Thermo Scientific). Primers and probe combinations are provided in
Table 2.
Immunohistochemistry. Prior to cutting, brains were cryoprotected by
submergence in 30% sucrose and 1% sodium azide in 0.1 M PBS at 6 1C for 48 h.
Brains were cut into 30mm coronal sections. The sections were immersed in 0.3%
H2O2 in Tris-buffered saline (TBS) for 30 min to quench endogenous peroxidase
activity. Sections were treated with 10 mmol/l, pH 6.0, sodium citrate buffer for
10 min at 99 1C for antigen retrieval (except for the pPERK antibody) and
subsequently incubated with primary antibodies at room temperature overnight.
Antibodies (Table 1) were diluted in TBS containing 0.5% Triton X-100.
Negative controls for all immunostainings were generated by omission of primary
antibodies. Sections were washed with TBS. For the single staining, the
sections were subsequently incubated for 120 min with undiluted EnVision/HRP
anti-rabbit/mouse (Dako, Hamburg, Germany). Color was developed using 3,
30-diaminobenzidine (EnVision detection system/HRP 1 : 50, DakoCytomation,
Glostrup, Denmark) as a chromogen. After fixing sections on glass slides they
were counterstained with hematoxylin and mounted using Depex (BDH
Laboratories Supplies, East Grinstead, UK). For the double-immunofluorescence
staining, the sections were incubated with either pPERK or pIRE1a at room
temperature overnight and subsequently incubated for 120 min with undiluted
EnVision/HRP anti-rabbit (Dako). Color was developed using rhodamine
tyramine (1 : 3000, 0.03% H2O2, 5 min), which was made as previously
described.47 Afterwards sections were incubated overnight with AT8-BIO
(Thermo Scientific) and streptavidin ALEXA488 (1 : 500, Life Technologies,
Carlsbad, CA, USA) for 120 min. Finally, the sections were mounted using
vectashield.
Immunohistochemical images were obtained on an Olympus BX41 (Olympus,
Tokyo, Japan) using cell^D software (Olympus). For quantification of UPR activation
and p-tau, a representative area in the cortex, hippocampus and striatum of each
animal was acquired with  20 objective. The same microscope settings were used
for all animals. ImageJ software with threshold color plugin was used to quantify the
area of interest that was immunoreactive for pIRE1a, pPERK and AT8 antibody. An
area with positive reactivity was selected to determine the threshold. The threshold
was the same for all brain areas and torpor stages. Each image was converted to an
8-bit binary image to measure the surface of positive pixels. The spatial correlation of
pIRE1a, pPERK and AT8 was analyzed on a Leica TCS-SP2 confocal microscope
(Leica, Wetzlar, Germany). For quantification, 40 cells with positive reactivity for one of
the antibodies were analyzed three times. The percentage of cells positive for pIRE1a,
pPERK or AT8 and the percentage of cells positive for both pPERK and AT8 or
pIRE1a and AT8 was calculated.
Statistical analysis. GraphPad Prism software was used for graphs and
statistical analysis. The qPCR data are presented as mean±S.D., the other
experiments are presented as mean±S.E.M. Data represent independent
experiments of n¼ 3 or more. All data are normalized and compared with the
untreated 37 1C control sample. For multiple statistical comparisons ANOVA,
Tukey test was used. Two-sided unpaired Student’s t-test was used for single
statistical comparison. No significance difference was defined as P40.05.
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Table 1 Primary antibodies
Antibody Species Dilution Company
Antibodies for western blot analyses
BiP/GRP78 Goat 1 : 1000 in 5% BSA/TBS-T Santa-Cruz, Dallas, TX, USA
eEF2a Rabbit 1 : 1000 in 5% BSA/TBS-T Cell Signaling, Danvers, MA, USA
p-eIF2a Rabbit 1 : 500 in 5% BSA/TBS-T Abcam, Cambridge, UK
PERK Goat 1 : 500 in 5% BSA/TBS Santa-Cruz
pPERK Rabbit 1 : 500 in 5% BSA/TBS Santa-Cruz
Total eIF2a Rabbit 1 : 500 in 5% BSA/TBS-T Cell Signaling
Tau Rabbit 1 : 1000 in 2.5% milk/PBS-T DAKO
p-tau (Ser396) Mouse 1 : 1000 in 1% BSA/PBS-T Cell Signaling
Antibodies for immunohistochemistry
AT8 Mouse 1 : 2000 (single) Pierce, Rockford, IL, USA
AT8-BIO Mouse 1 : 500 (double) Thermo scientific
pIRE1a Rabbit 1 : 80.000 (single), 1 : 20.000 (double) Novus Biologicals, Littleton, CO, USA
pPERK (Thr980) Rabbit 1 : 4000 (single), 1 : 400 (double) Santa-Cruz







BiP fw: catcaagttcttgccgttca 10 99
rev: tcttcaggagcaatgtcttgt
CHOP fw: aaggcactgagcgtatcatgt 21 105
rev: tgaagatacacttccttcttgaaca
GAPDH fw: tccactggcgtcttcacc 45 78
rev: ggcagagatgatgaccctttt
eEF2a fw: caatggcaaaatctcactgc 63 122
rev: aacctcatctctattaaaaacaccaaa
Probe numbers refer to numbers in the Roche universal probe library
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